HC Biologics is a biotechnology company that develops, manufactures, and distributes advanced regenerative tissue products, orthopedic implants, and customized surgical solutions for spinal, trauma, and reconstructive procedures. Pulse 2.0 interviewed HC Biologics President and CEO Husnu Ceylan to learn more.
Husnu Ceylan’s Background
Husnu “HC” Ceylan
Could you tell me more about your background and what shaped your career in biotechnology? Ceylan said:
“I was born and raised in Turkey and built my academic and professional foundation across three countries—Turkey, Germany, and the United States. I came from humble beginnings, with no family wealth or industry connections. Everything I have achieved came from perseverance, discipline, and a commitment to creating meaningful impact in global healthcare.”
“Over nearly 20 years in the international medical and pharmaceutical industry, I have worked across medical products development, global distribution, regulatory strategy, and biologics innovation. These experiences allowed me to establish over $450 million in cumulative global sales throughout my professional career, collaborate with some of the world’s leading surgeons and medical institutions, and build multinational medical operations from the ground up.”
“Today, HC Biologics distributes advanced biologics and surgical solutions in close to 60 countries, and the foundation of that success lies in my early experiences—learning to work harder than my circumstances and refusing to accept limitations.”
Formation Of The Company
How did the idea for HC Biologics come together? Ceylan shared:
“During my work with tissue banks, hospitals, and global distributors, I identified a clear unmet need:
Surgeons around the world lacked consistent access to high-quality allografts & medical devices, and patients often received unequal standards of care based solely on geography.
I founded HC Biologics to close that gap.
We built a biotechnology and medical device company focused on developing and distributing premium allografts, spinal fixation systems, neuro access tools, orthopedics devices and regenerative solutions —all supported by the most reputable U.S. tissue banks & medical device manufacturing facilities and state-of-the-art production technologies.
We are also proud to operate as an ISO 9001 and ISO 13485 certified medical device manufacturer, ensuring full compliance with FDA, GMP, CE/MDR, and international regulatory directives.
Our philosophy is simple:
A patient anywhere in the world should have access to the same level of biologics and medical devices as a patient in the top U.S. hospitals.”
Work As CEO
What are your primary responsibilities as CEO? Ceylan noted:
“My leadership focuses on four core responsibilities:
- Global strategy and expansion across North America, Latin America, Europe, the Middle East, and Asia.
- Product innovation across allografts, spinal and orthopedic systems, neuro solutions, regenerative technologies, and minimally invasive procedures.
- Regulatory and compliance oversight, ensuring that every product meets FDA, CE, ISO, GMP, and international standards.
- Building strategic partnerships with hospitals, surgeons, research institutions, and U.S. tissue banks.”
Favorite Memory
What has been your favorite memory while leading HC Biologics? Ceylan reflected:
“Without exception, my most meaningful memories come from surgeons sharing clinical outcomes where our products—whether an allograft, an OsteoPoint spinal fixation system, or a custom OsteoPoint cranial implant—directly changed a patient’s life.
It is especially profound in pediatric oncology cases. In some situations, a child is at real risk of losing a limb; yet through the gift of donation from a generous donor and the structural allografts we provide, that limb can be saved.
Those moments define our purpose and validate everything we do.
I also take great pride in watching our international teams grow—seeing all our global offices work together toward one mission: advancing biologics and improving patient outcomes worldwide.”
Core Products
What are the company’s core products and technologies? Ceylan explained:
“HC Biologics offers one of the most diversified biologics and surgical portfolios in the industry, including:
Allografts
- Bone particulates, DBM (Demineralized Bone Matrix) Putty/Crunch/Gel/Fiber, structural allografts, amniotic membranes, ADM (Acellular Dermal Matrix)
- Comprehensive allografts for spine, orthopedics, trauma, oncology, neuro, and oral-maxillofacial surgery
- All processed through leading U.S. FDA-registered and AATB (American Association of Tissue Bank) accredited tissue banks
OsteoPoint Surgical Technologies
- OsteoPoint Spinal Fixation Systems (cervical, thoracolumbar, lateral, MIS)
- OsteoPoint Craniomaxillofacial (CMF) Implants
- OsteoPoint Neuro Access Needle
- OsteoPoint Hip, Knee & Shoulder Spacers
These systems are engineered for precision, stability, and intraoperative versatility.
CellRise Regenerative Portfolio
- CellRise Platelet Rich Plasma (PRP) System
- CellRise Acellular Dermal Matrix
- CellRise Hemostat Line
Designed to enhance healing, reduce intraoperative bleeding, and support soft-tissue reconstruction.
Synth Kyphoplasty, Vertebroplasty & Bone Cements
- High-performance vertebral augmentation kits
- Spinal and orthopedic bone cements with FDA and CE clearance
This broad portfolio enables HC Biologics to serve multiple surgical specialties and deliver end-to-end biologic and medical device solutions for hospitals and surgeons worldwide.”
Challenges Faced
What challenges have you faced recently, and how did you overcome them? Ceylan acknowledged:
“Key challenges include:
- Growing worldwide regulatory complexity across FDA, CE/MDR, COFEPRIS, INVIMA, DIGEMID, MFDS, PMDA, and others
- Post-COVID global supply chain volatility
- Increasing worldwide demand for high-quality allografts and biologics
We overcame these challenges by:
- Establishing 9 international offices to decentralize logistics and improve responsiveness
- Strengthening partnerships with the most reputable U.S. tissue banks
- Expanding internal R&D across biologics, regenerative solutions, and spinal systems
- Building a highly resilient manufacturing and distribution infrastructure
These measures allowed HC Biologics to maintain product continuity even when competitors experienced shortages.”
Evolution Of The Company’s Technology
How has the company’s technology evolved since launching? Ceylan noted:
HC Biologics began as a biologics-focused distribution company and has evolved into an integrated biotechnology and medical device manufacturer.
Our advancements include:
- New demineralization and processing techniques to enhance osteoinductivity
- Expansion of the OsteoPoint line into multiple fixation, CMF, neuro, and spacer systems
- Clinical advancements through the CellRise regenerative product family
- FDA- and CE-cleared Synth kyphoplasty/vertebroplasty systems and bone cements
- Trauma, ortho, and sports medicine offerings are compliant with the strict European MDR
Our evolution reflects continuous surgeon collaboration, global experience, and a commitment to innovation.
Milestones
What major milestones has HC Biologics achieved? Ceylan cited:
“Key milestones include:
- Expansion to 9 international offices
- Commercial presence in close to 60 countries
- Over $450 million in total global sales impact across my leadership career
- Partnerships with leading U.S. tissue banks
- Launch of FDA-, CE-, and ISO-certified medical device families
- Development of the OsteoPoint, CellRise, and Synth product lines
- ISO 9001 & ISO 13485 certification as a medical device manufacturer
These milestones reinforce our position as a globally recognized biologics and surgical solutions provider.”
Total Addressable Market (TAM)
What is the total addressable market (TAM) you are pursuing? Ceylan assessed:
“Biologics for spine, trauma, orthopedics, oncology, dental, and sports medicine represent a $12+ billion global market.
When combined with spinal fixation systems, vertebral augmentation systems, bone cements, PRP technologies, and regenerative products, our TAM exceeds $20 billion worldwide.
Our reach into nearly 60 countries allows us to participate in both established and rapidly growing markets.”
Differentiation From The Competition
What differentiates HC Biologics from competitors? Ceylan affirmed:
- Global Reach + Local Execution
Our 9-country footprint enables regulatory expertise, real-time logistics, and local surgeon support. - Full Portfolio with Strong Regulatory Clearances
Few companies globally offer FDA- and CE-cleared:
- Spinal fixation systems
- Vertebroplasty & kyphoplasty systems
- Bone cements
- PRP, hemostatic, and dermal matrix solutions
- Orthopedic, neuro, and CMF implants
…paired with a premium allograft portfolio.
- Partnerships with Leading U.S. Tissue Banks – Surgeons trust our biologics because they are sourced and processed in the USA to the highest U.S. standards by FDA-cleared and AATB-accredited tissue banking partners.
HC Biologics is not a single-product supplier—we are a full biologics and medical device ecosystem.
Future Company Goals
What are the company’s future goals? Ceylan emphasized:
Our next phase focuses on:
- Expanding our R&D pipeline in biologics and regenerative medicine
- Scaling the OsteoPoint and CellRise product families
- Strengthening distribution hubs across Europe, the Middle East, and Southeast Asia
- Developing new minimally invasive biologic and spinal technologies
- Enhancing global logistics and surgeon education programs
Our long-term vision is to become a global leader in biologics, regenerative solutions, and advanced surgical technologies.”
Additional Thoughts
Any final thoughts? Ceylan concluded:
“Biologics are entering their most transformative decade. As someone who started with very little and built an international biotechnology company through persistence and purpose, I am committed to ensuring that every patient—regardless of geography—receives the highest quality biologic care.”
“HC Biologics will continue innovating, expanding globally, and setting new standards for biologics and surgical solutions worldwide. To learn more about HC Biologics, please visit www.
